LMO1 and neuroblastoma: First, LMO1 rs110419 was shown to significantly decrease the risk of neuroblastoma (heterogeneous: adjusted OR = 0.62, 95% CI = 0.46–0.82; homogenous: adjusted OR = 0.65, 95% CI = 0.44–0.97; additive: adjusted OR = 0.76, 95% CI = 0.63–0.92; dominant: adjusted OR = 0.63, 95% CI = 0.48–0.82).